This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Tricida Dirección

Dirección controles de criterios 3/4

Tricida's CEO is Gerrit Klaerner, appointed in Aug 2013, they has a tenure of 9.83 years. Their total yearly compensation is $4.68M , comprised of 12.8% salary and 87.2% bonuses, including company stock and options. They directly owns 0.68% of the company’s shares, worth $3.93. The average tenure of the management team and the board of directors is 4 years and 9.5 years respectively.

Información clave

Gerrit Klaerner

Chief Executive Officer (CEO)

US$4.7m

Compensación total

Porcentaje del salario del CEO	12.8%
Permanencia del CEO	9.8yrs
Participación del CEO	0.7%
Permanencia media de la dirección	4yrs
Promedio de permanencia en la Junta Directiva	9.5yrs

Actualizaciones recientes de la dirección

Recent updates

Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares

Dec 14

Tricida revises VALOR-CKD trial protocol, updates patent protection, shares down 14%

Dec 09

Tricida's Veverimer CRL And Regulatory Updates: An Analysis

Nov 17

Tricida slumps 46% on FDA feedback on veverimer proposal; launches cost-cutting initiatives

Oct 29

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gerrit Klaerner en comparación con los beneficios de Tricida?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2022	n/a	n/a	-US$134m
Jun 30 2022	n/a	n/a	-US$148m
Mar 31 2022	n/a	n/a	-US$153m
Dec 31 2021	US$5m	US$600k	-US$177m
Sep 30 2021	n/a	n/a	-US$181m
Jun 30 2021	n/a	n/a	-US$219m
Mar 31 2021	n/a	n/a	-US$244m
Dec 31 2020	US$9m	US$598k	-US$265m
Sep 30 2020	n/a	n/a	-US$268m
Jun 30 2020	n/a	n/a	-US$235m
Mar 31 2020	n/a	n/a	-US$213m
Dec 31 2019	US$10m	US$584k	-US$177m
Sep 30 2019	n/a	n/a	-US$146m
Jun 30 2019	n/a	n/a	-US$131m
Mar 31 2019	n/a	n/a	-US$120m
Dec 31 2018	US$1m	US$503k	-US$103m
Sep 30 2018	n/a	n/a	-US$96m
Jun 30 2018	n/a	n/a	-US$77m
Mar 31 2018	n/a	n/a	-US$60m
Dec 31 2017	US$821k	US$425k	-US$41m

Compensación vs. Mercado: Gerrit's total compensation ($USD4.68M) is above average for companies of similar size in the US market ($USD747.42K).

Compensación vs. Ingresos: Gerrit's compensation has been consistent with company performance over the past year.

CEO

Gerrit Klaerner (51 yo)

9.8yrs

Permanencia

US$4,676,490

Compensación

Dr. Gerrit Klaerner, Ph.D. Founded Tricida, Inc.and has been its Chief Executive Officer and President since August 2013 and has been its an Executive Director since July 2013. Dr. Klaerner was the Founder...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gerrit Klaerner	Founder	9.8yrs	US$4.68m	0.68% $ 3.9
Geoffrey Parker	COO, CFO & Executive VP	6.2yrs	US$2.51m	0.72% $ 4.2
Robert McKague	Executive VP	3.3yrs	US$2.43m	0.031% $ 0.2
Dawn Parsell	Executive Vice President of Clinical Development	4.8yrs	US$2.77m	0.0060% $ 0.03
Annie Yoshiyama	VP of Finance & Chief Accounting Officer	2.5yrs	sin datos	sin datos
Jackie Cossmon	Vice President of Investor Relations & Communications	no data	sin datos	sin datos
Edward Hejlek	Executive Vice President of Intellectual Property	3.3yrs	US$2.10m	sin datos

4.0yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: TCDA.Q's management team is considered experienced (4 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gerrit Klaerner	Founder	9.9yrs	US$4.68m	0.68% $ 3.9
Kathryn Falberg	Independent Non-Employee Director	5.1yrs	US$329.00k	0.074% $ 0.4
Klaus Veitinger	Independent Chairman of the Board	9.3yrs	US$379.00k	0.20% $ 1.1
David Hirsch	Independent Non-Employee Director	6.9yrs	US$326.50k	0.019% $ 0.1
Robert Alpern	Independent Non-Employee Director and Member of Scientific & Clinical Advisory Board	9.7yrs	US$314.00k	sin datos
John Fordtran	Member of Scientific & Clinical Advisory Board	no data	sin datos	sin datos
David Bushinsky	Member of Scientific & Clinical Advisory Board	no data	sin datos	sin datos
Craig Hawker	Member of Scientific & Clinical Advisory Board	no data	sin datos	sin datos
Sandra Coufal	Independent Non-Employee Director and Member of Scientific & Clinical Advisory Board	9.9yrs	US$316.50k	0.15% $ 0.9
Navdeep Tangri	Member of Scientific & Clinical Advisory Board	no data	sin datos	sin datos
Thomas Hostetter	Member of Scientific & Clinical Advisory Board	no data	sin datos	sin datos
Bertram Pitt	Member of Scientific and Clinical Advisory Board	no data	sin datos	sin datos

9.5yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: TCDA.Q's board of directors are considered experienced (9.5 years average tenure).

This company is no longer active

Tricida Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Tricida, Inc. Announces Resignation of David Bonita as Director

Insufficient new directors

Insufficient new directors

Tricida, Inc., Annual General Meeting, Jun 15, 2022

Board Member notifies of intention to sell stock

Board Member notifies of intention to sell stock

Recent updates

Tricida, Inc. Announces Resignation of David Bonita as Director

Tricida, Inc.(OTCPK:TCDA.Q) dropped from NASDAQ Composite Index

Tricida Receives Delisting Notice from Nasdaq

Motion for Asset Sale Filed by Tricida, Inc.

Tricida, Inc. Filed for Bankruptcy

Tricida Receives Non-Compliance Notice from Nasdaq

Tricida Receives A Notice from Nasdaq Regarding Minimum Bid Price

Price target decreased to US$8.00

Insufficient new directors

Tricida, Inc Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

Price target decreased to US$15.33

Tricida, Inc. announced that it expects to receive $125 million in funding

Tricida enters $125M debt facility

Tricida: Important Binary Event Coming Up

Tricida, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Price target increased to US$16.75

Price target decreased to US$15.50

Tricida, Inc Announces Administrative Stop of the VALOR-CKD Trial

Tricida, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$17.50

Insufficient new directors

Tricida, Inc., Annual General Meeting, Jun 15, 2022

Price target increased to US$17.50

Tricida, Inc. Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in Ukraine

Board Member notifies of intention to sell stock

Price target increased to US$20.00

Calculating The Intrinsic Value Of Tricida, Inc. (NASDAQ:TCDA)

Board Member notifies of intention to sell stock

Tricida, Inc.(NasdaqGS:TCDA) dropped from Russell 2500 Growth Index

Board Member notifies of intention to sell stock

Tricida, Inc. Provides Update on FDA Interactions

Tricida, Inc. Appoints Geoffrey Parker as Chief Operating Officer

Robbins Geller Rudman & Dowd LLP Announces Lead Plaintiff Deadline in the Tricida, Inc. Class Action Lawsuit

New 90-day low: US$6.57

Board Member notifies of intention to sell stock

Block & Leviton LLP Sues Tricida, Inc. for Violations of the Federal Securities Laws

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Tricida, Inc

Law Offices of Howard G. Smith Announces the Filing of Securities Class Action on Behalf of Tricida, Inc. Investors

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Tricida, Inc

Board Member notifies of intention to sell stock

Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares

CFO & Executive VP recently bought US$102k worth of stock

Tricida, Inc. Announces Updates on Veverimer Development Program, Regulatory Status and New Patent Extending Protection Through 2038

Tricida revises VALOR-CKD trial protocol, updates patent protection, shares down 14%

Tricida, Inc. Announces Executive Changes

Tricida's Veverimer CRL And Regulatory Updates: An Analysis

Price target lowered to US$13.50

Price target raised to US$22.67

Tricida, Inc. Announces Susannah Cantrell Will Depart from the Position as Executive Vice President and Chief Commercial Officer, Effective from October 30, 2020

Tricida slumps 46% on FDA feedback on veverimer proposal; launches cost-cutting initiatives

New 90-day low: US$8.29

New 90-day low: US$9.33

Tricida, Inc.(NasdaqGS:TCDA) dropped from S&P Pharmaceuticals Select Industry Index

New 90-day low - US$13.24

Price target lowered to US$45.33

New 90-day low - US$15.64

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad